GO:0016403 dimethylargininase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016403 (dimethylargininase activity) catalyzes the hydrolysis of N(G),N(G)-dimethyl-L-arginine (ADMA) to dimethylamine and L-citrulline, a key reaction in the regulation of nitric oxide synthase (NOS).
• The enzyme, also known as DDAH (dimethylarginine dimethylaminohydrolase), exists as two main isoforms, DDAH1 and DDAH2, which control intracellular ADMA levels and thus NOS activity.
• DDAH1 is a zinc-binding enzyme; its activity can be regulated by S-nitrosylation of a critical cysteine residue, linking it to redox signaling.
• Dysregulated DDAH/ADMA pathway is implicated in cardiovascular disease, critical illness, and cancer progression, including lung adenocarcinoma and chemoresistance in nasopharyngeal carcinoma.
• Renal asymmetric dimethylarginine (ADMA) inhibits fibrosis, suggesting a protective role for DDAH activity in kidney tissue.
• Studying dimethylargininase activity requires methods such as enzyme assays, knockout/knock-in models, and proteomic analysis of ADMA metabolism.
Description
Dimethylargininase activity (GO:0016403) is a molecular function that catalyzes the hydrolysis of N(G),N(G)-dimethyl-L-arginine (asymmetric dimethylarginine, ADMA) to dimethylamine and L-citrulline. This reaction is central to the regulation of nitric oxide (NO) production because ADMA is an endogenous inhibitor of nitric oxide synthase (NOS); by degrading ADMA, dimethylargininase activity relieves NOS inhibition and promotes NO signaling. The enzyme responsible, dimethylarginine dimethylaminohydrolase (DDAH), exists in two isoforms, DDAH1 and DDAH2, which are widely expressed in mammalian tissues and play distinct roles in vascular and immune biology. Research on dimethylargininase activity has expanded beyond cardiovascular physiology into cancer biology, where DDAH1 has been shown to promote lung adenocarcinoma progression through STAT1-mediated transcriptional activation and to drive cisplatin chemoresistance in nasopharyngeal carcinoma via the EGFR-JAK2-STAT3 pathway. In critical illness, ADMA levels are elevated and correlate with endothelial dysfunction, making DDAH a potential therapeutic target. The enzyme is also a zinc-binding protein, and its activity is sensitive to redox modifications such as S-nitrosylation, which provides a mechanistic link between nitrosative stress and NO bioavailability. Given its role in NO regulation and disease, dimethylargininase activity is a compelling subject for functional genomics and drug discovery. Understanding its catalytic mechanism, regulation, and genetic control is essential for developing targeted therapies and for interpreting biomarker data in clinical studies.
dimethylargininase activity At A Glance
| GO ID | GO:0016403 |
|---|---|
| GO term | dimethylargininase activity |
| Ontology | molecular_function |
| Synonym | dimethylarginine dimethylaminohydrolase activity; N(G),N(G)-dimethylarginine dimethylaminohydrolase activity; NG,NG-dimethylarginine dimethylaminohydrolase activity; NG,NG-dimethyl-L-arginine dimethylamidohydrolase activity |
| Major function | Hydrolysis of N(G),N(G)-dimethyl-L-arginine (ADMA) to dimethylamine and L-citrulline, regulating nitric oxide synthase activity. |
| Enzyme class | Hydrolase (EC 3.5.3.18) |
| Cofactor | Zinc ion (Zn2+) binding site identified in bovine brain dimethylargininase. |
| Subcellular location | Cytoplasm (DDAH1 and DDAH2 are primarily cytosolic). |
| Tissue distribution | Widely expressed, with high levels in liver, kidney, and vascular endothelium. |
What Is GO:0016403?
Dimethylargininase activity (GO:0016403) is defined as the catalysis of the reaction: N(G),N(G)-dimethyl-L-arginine + H2O = dimethylamine + L-citrulline. In simpler terms, it is an enzyme activity that removes a methylated arginine derivative (ADMA) by hydrolyzing it into two products, thereby controlling the levels of this endogenous NOS inhibitor.
Why Is dimethylargininase activity Important in Cell Biology?
Dimethylargininase activity is critically important because it controls the bioavailability of ADMA, an endogenous inhibitor of all nitric oxide synthase isoforms. By degrading ADMA, DDAH enzymes regulate NO production, which influences vascular tone, endothelial function, and immune responses. Dysregulation of this activity leads to ADMA accumulation, endothelial dysfunction, and has been linked to cardiovascular disease, critical illness, and cancer progression. Moreover, the enzyme's sensitivity to S-nitrosylation provides a feedback mechanism linking nitrosative stress to NO signaling.
• Regulates nitric oxide synthase (NOS) activity by degrading the endogenous inhibitor ADMA.
• Modulates vascular tone and endothelial function; ADMA accumulation is a risk factor for cardiovascular disease.
• Implicated in critical illness, where elevated ADMA correlates with severity and organ dysfunction.
• Promotes cancer progression: DDAH1 enhances lung adenocarcinoma via STAT1-mediated transcriptional activation.
• Drives chemoresistance in nasopharyngeal carcinoma through the EGFR-JAK2-STAT3 pathway.
• Renal ADMA inhibits fibrosis, suggesting a protective role for DDAH activity in kidney tissue.
• Zinc-dependent catalysis and redox regulation via S-nitrosylation link DDAH to cellular stress responses.
• Potential therapeutic target for diseases associated with endothelial dysfunction and cancer.
• Biomarker potential: ADMA levels reflect DDAH activity and are measured in clinical studies.
• Subject to genetic and pharmacological manipulation for functional studies.
Molecular Mechanism of dimethylargininase activity
Substrate Binding and Catalysis
In simple terms: The enzyme grabs ADMA and splits it into two harmless molecules.
Dimethylargininase catalyzes the hydrolysis of N(G),N(G)-dimethyl-L-arginine (ADMA) to dimethylamine and L-citrulline. The reaction proceeds through a zinc-dependent mechanism, as the enzyme from bovine brain contains a zinc binding site essential for activity. The substrate ADMA binds to the active site, where a water molecule attacks the guanidinium group, leading to cleavage and release of dimethylamine and citrulline.
Zinc Cofactor and Active Site
In simple terms: A zinc atom in the enzyme's core helps it work properly.
Bovine brain dimethylargininase was shown to contain a zinc binding site, and zinc is required for catalytic activity. The Zn(II) ion is coordinated by conserved residues and is essential for substrate turnover. Removal of zinc results in loss of activity, and the enzyme can be inhibited by specific Cys-S-nitrosylation, which likely disrupts zinc coordination or substrate binding.
Redox Regulation by S-Nitrosylation
In simple terms: Nitric oxide can attach to a cysteine in the enzyme and turn it off.
Dimethylargininase-1 (DDAH-1) is inhibited upon specific Cys-S-nitrosylation, as demonstrated with the Zn(II)-free enzyme. S-nitrosothiols react with cysteine hydrolases, and comparative studies show that DDAH-1 is particularly sensitive to S-nitrosylation, which may serve as a feedback mechanism to regulate NO production. This redox modification links nitrosative stress to ADMA degradation and NOS activity.
Isoforms and Tissue Distribution
In simple terms: There are two main versions of the enzyme, DDAH1 and DDAH2, with different jobs.
Two isoforms, DDAH1 and DDAH2, exhibit dimethylargininase activity but differ in tissue distribution and regulation. DDAH1 is widely expressed and is the predominant isoform in many tissues, while DDAH2 is more restricted. Both isoforms contribute to ADMA clearance, but DDAH1 has been more extensively studied in cancer and cardiovascular disease.
Role in Nitric Oxide Synthesis
In simple terms: By destroying the inhibitor ADMA, the enzyme allows NO to be made.
ADMA is an endogenous inhibitor of nitric oxide synthase (NOS). Dimethylargininase activity degrades ADMA, thereby relieving NOS inhibition and promoting NO production. This regulatory loop is critical for maintaining endothelial function, and its disruption leads to ADMA accumulation and endothelial dysfunction.
Key Genes Involved in GO:0016403 dimethylargininase activity
The following genes and proteins are directly involved in dimethylargininase activity, ADMA metabolism, and related signaling pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DDAH1 | Encodes dimethylargininase-1, a major enzyme degrading ADMA | Knockout and overexpression models show effects on NO signaling and cancer progression. |
| DDAH2 | Encodes dimethylargininase-2, an isoform with distinct tissue distribution | Studied for its role in vascular and immune function. |
| NOS1 (nNOS) | Neuronal nitric oxide synthase, inhibited by ADMA | Target for understanding ADMA regulation in neurons. |
| NOS2 (iNOS) | Inducible nitric oxide synthase, inhibited by ADMA | Relevant in inflammation and cancer. |
| NOS3 (eNOS) | Endothelial nitric oxide synthase, inhibited by ADMA | Key in endothelial function and cardiovascular disease. |
| PRMT1 | Protein arginine methyltransferase that generates ADMA | Source of ADMA; studied in conjunction with DDAH. |
| PRMT5 | Protein arginine methyltransferase, generates symmetric dimethylarginine | Related to ADMA metabolism. |
| STAT1 | Transcription factor that activates DDAH1 expression | Mediates DDAH1 upregulation in lung adenocarcinoma. |
| EGFR | Receptor tyrosine kinase upstream of JAK2-STAT3 | Drives DDAH1 expression in chemoresistant nasopharyngeal carcinoma. |
| JAK2 | Janus kinase 2, part of EGFR-JAK2-STAT3 pathway | Involved in DDAH1-mediated chemoresistance. |
| STAT3 | Transcription factor downstream of JAK2 | Activates DDAH1 and promotes chemoresistance. |
| HMGA1 | Chromatin architectural protein that promotes DDAH1 transcription | Linked to lung adenocarcinoma progression. |
| CTPS1 | CTP synthetase, a cysteine hydrolase like DDAH1 | Comparative studies on S-nitrosylation. |
| CBS | Cystathionine beta-synthase, related to ADMA metabolism | Potential cross-talk in sulfur amino acid metabolism. |
| GATM | Glycine amidinotransferase, involved in creatine synthesis and ADMA production | Contributes to ADMA pool. |
| AGXT2 | Alanine-glyoxylate aminotransferase 2, degrades ADMA | Alternative ADMA clearance pathway. |
| SLC7A1 | Cationic amino acid transporter, imports ADMA | Regulates intracellular ADMA levels. |
| SLC7A2 | Cationic amino acid transporter, imports ADMA | Regulates intracellular ADMA levels. |
How Is dimethylargininase activity Regulated?
Dimethylargininase activity is regulated at multiple levels. Transcriptionally, DDAH1 is activated by STAT1 downstream of HMGA1 in lung adenocarcinoma and by the EGFR-JAK2-STAT3 pathway in nasopharyngeal carcinoma. Post-translationally, DDAH1 activity is inhibited by S-nitrosylation of a critical cysteine residue, providing a feedback loop that senses nitrosative stress. Additionally, the enzyme requires zinc for activity, and zinc availability may influence its function. In critical illness, inflammatory cytokines and oxidative stress can modulate DDAH expression and activity, contributing to elevated ADMA levels.
dimethylargininase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DDAH1 | Lung adenocarcinoma progression | DDAH1 knockout and overexpression in lung cancer cell lines |
| DDAH1 | Cisplatin chemoresistance in nasopharyngeal carcinoma | DDAH1 knockout in nasopharyngeal carcinoma cells treated with cisplatin |
| DDAH1 | Cardiovascular disease and endothelial dysfunction | Endothelial-specific DDAH1 knockout mice |
| DDAH1 | Renal fibrosis | DDAH1 knockout or overexpression in kidney fibrosis models |
| DDAH1 | Critical illness and sepsis | DDAH1 knockout mice subjected to sepsis models |
Cancer Progression and Chemoresistance
DDAH1 promotes lung adenocarcinoma progression through STAT1-mediated transcriptional activation, and high DDAH1 expression correlates with poor prognosis. In locally advanced nasopharyngeal carcinoma, DDAH1 drives cisplatin chemoresistance via the EGFR-JAK2-STAT3 pathway, suggesting that targeting DDAH1 could overcome resistance. These findings highlight dimethylargininase activity as a potential therapeutic target in oncology.
Cardiovascular and Endothelial Dysfunction
ADMA is an endogenous inhibitor of NOS, and its accumulation due to reduced dimethylargininase activity leads to endothelial dysfunction and cardiovascular disease. Elevated ADMA levels are associated with hypertension, atherosclerosis, and heart failure, making DDAH a key regulator of vascular health.
Critical Illness and Organ Dysfunction
In critical illness, ADMA levels are elevated and correlate with disease severity and organ dysfunction. The DDAH/ADMA/NOS pathway is dysregulated in sepsis and other critical conditions, contributing to microvascular dysfunction and organ failure.
Renal Fibrosis
Renal asymmetric dimethylarginine inhibits fibrosis, suggesting that ADMA, the substrate of dimethylargininase, may have protective effects in kidney tissue. This paradoxical role indicates that the balance between ADMA production and degradation is crucial for renal homeostasis.
From dimethylargininase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does DDAH1 loss affect ADMA levels and NOS activity? | DDAH1 knockout cell lines or mice |
| Does a specific point mutation in DDAH1 alter its catalytic activity? | Point mutation knock-in via CRISPR |
| Does DDAH1 overexpression promote cancer progression? | DDAH1 overexpression in cancer cell lines |
| How does S-nitrosylation regulate DDAH1 activity? | Cysteine-to-serine point mutant knock-in |
| What is the role of DDAH1 in chemoresistance? | DDAH1 knockout in chemoresistant cancer cells |
| Can DDAH1 be tagged for live-cell imaging? | Tagged knock-in of DDAH1 with fluorescent protein |
How to Study the dimethylargininase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Citrulline assay | Dimethylargininase enzymatic activity | In vitro enzyme kinetics and inhibitor testing |
| LC-MS/MS | ADMA and SDMA concentrations | Clinical biomarker studies and cell culture |
| Western blot | DDAH1 protein expression | Tissue and cell line analysis |
| Immunoprecipitation | Protein-protein interactions and S-nitrosylation | Mechanistic studies of DDAH1 regulation |
| CRISPR knockout | Loss-of-function phenotypes | Functional genomics of DDAH1 in disease models |
| Overexpression | Gain-of-function phenotypes | Cancer progression and drug resistance studies |
| Site-directed mutagenesis | Specific amino acid function | Mapping catalytic residues and regulatory sites |
| RNA-seq | Transcriptional changes upon DDAH1 manipulation | Pathway analysis and biomarker discovery |
Enzyme Activity Assays
Dimethylargininase activity can be measured using colorimetric or fluorometric assays that detect the formation of L-citrulline from ADMA. These assays are used to quantify enzyme kinetics and inhibitor effects.
ADMA Quantification by Mass Spectrometry
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for measuring ADMA and symmetric dimethylarginine (SDMA) in biological samples, providing insights into DDAH activity in vivo.
Western Blotting and Immunoprecipitation
Western blotting with DDAH1-specific antibodies is used to assess protein expression levels, while immunoprecipitation can pull down DDAH1 to study post-translational modifications such as S-nitrosylation.
CRISPR-Based Genetic Screens
Genome-wide CRISPR knockout screens can identify genes that regulate ADMA levels or DDAH1 expression, uncovering novel components of the pathway.
How CRISPR Can Be Used to Study GO:0016403 dimethylargininase activity
Knockout
CRISPR knockout of DDAH1 or DDAH2 is used to abolish dimethylargininase activity, leading to ADMA accumulation and reduced NO production. Such models are valuable for studying the role of DDAH in cancer, cardiovascular disease, and critical illness.
Point Mutation
Point mutations can be introduced into the DDAH1 gene to study the catalytic mechanism, zinc binding, or S-nitrosylation sites. For example, mutating the critical cysteine residue involved in S-nitrosylation can reveal its role in redox regulation.
Knock-in
Knock-in of tagged DDAH1 (e.g., GFP or FLAG) allows for live-cell imaging and protein interaction studies. This approach helps track DDAH1 localization and dynamics under physiological and pathological conditions.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of DDAH1 is used to increase dimethylargininase activity, which can reduce ADMA levels and enhance NO signaling. This is particularly useful for studying DDAH1's role in promoting cancer progression and chemoresistance.
How EDITGENE Supports dimethylargininase activity Research
Researchers studying dimethylargininase activity-related genes often need to determine whether a candidate gene is causally involved in ADMA metabolism, NO signaling, or disease progression. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for dimethylargininase activity research.
Frequently Asked Questions About dimethylargininase activity
What is dimethylargininase activity?
Dimethylargininase activity (GO:0016403) is the enzymatic hydrolysis of N(G),N(G)-dimethyl-L-arginine (ADMA) to dimethylamine and L-citrulline, regulating nitric oxide synthase.
What genes are involved in dimethylargininase activity?
The main genes are DDAH1 and DDAH2, which encode the two isoforms of the enzyme.
What is the role of DDAH1 in cancer?
DDAH1 promotes lung adenocarcinoma progression via STAT1-mediated transcriptional activation and drives cisplatin chemoresistance in nasopharyngeal carcinoma through the EGFR-JAK2-STAT3 pathway.
How is dimethylargininase activity regulated?
It is regulated transcriptionally by STAT1 and STAT3, and post-translationally by S-nitrosylation of a critical cysteine residue.
What diseases are associated with dimethylargininase activity?
Cardiovascular disease, critical illness, cancer, and renal fibrosis are associated with altered dimethylargininase activity.
What is the substrate of dimethylargininase?
The substrate is N(G),N(G)-dimethyl-L-arginine (ADMA), an endogenous inhibitor of nitric oxide synthase.
Does dimethylargininase require zinc?
Yes, bovine brain dimethylargininase contains a zinc binding site essential for activity.
How can I measure dimethylargininase activity?
Activity can be measured using citrulline assays, and ADMA levels can be quantified by LC-MS/MS.
What are the isoforms of dimethylargininase?
The two main isoforms are DDAH1 and DDAH2, encoded by separate genes.
Can CRISPR be used to study dimethylargininase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are widely used to study DDAH1 and DDAH2 functions.
Conclusion
Dimethylargininase activity (GO:0016403) is a critical molecular function that regulates nitric oxide signaling by degrading the endogenous NOS inhibitor ADMA. Its dysregulation is implicated in cardiovascular disease, critical illness, and cancer, making it a promising therapeutic target. Advances in CRISPR-based models and analytical methods continue to unravel the complex regulation and disease relevance of DDAH enzymes.
References
- 1. Tran CT et al.. 2003. The DDAH/ADMA/NOS pathway.. Atheroscler Suppl 4(4):33-40 PMID: 14664901
- 2. Hu T et al.. 2025. HMGA1 promotes the progression of lung adenocarcinoma through the STAT1-mediated transcriptional activation of DDAH1.. Biol Direct 20(1):101 PMID: 41035072
- 3. Yang JH et al.. 2025. DDAH1 Promotes Cisplatin Chemoresistance in Patients with Locally Advanced Nasopharyngeal Carcinoma via the EGFR-JAK2-STAT3 Pathway.. Adv Sci (Weinh) 12(30):e03647 PMID: 40538138
- 4. Wu M et al.. 2020. Renal asymmetric dimethylarginine inhibits fibrosis.. FEBS Open Bio 10(10):2003-2009 PMID: 32794631
- 5. Bogumil R et al.. 1998. Characterization of dimethylargininase from bovine brain: evidence for a zinc binding site.. Biochemistry 37(14):4791-8 PMID: 9537995
- 6. Brinkmann SJ et al.. 2014. Asymmetric dimethylarginine and critical illness.. Curr Opin Clin Nutr Metab Care 17(1):90-7 PMID: 24281375
- 7. Braun O et al.. 2007. Specific reactions of S-nitrosothiols with cysteine hydrolases: A comparative study between dimethylargininase-1 and CTP synthetase.. Protein Sci 16(8):1522-34 PMID: 17600152
- 8. Knipp M et al.. 2003. Zn(II)-free dimethylargininase-1 (DDAH-1) is inhibited upon specific Cys-S-nitrosylation.. J Biol Chem 278(5):3410-6 PMID: 12441345
